Seeking Alpha

Opexa Therapeutics (OPXA) +305% premarket on news it could be awarded up to $225M in a...

Opexa Therapeutics (OPXA) +305% premarket on news it could be awarded up to $225M in a commercialization deal struck with Merck Serono for its multiple sclerosis therapy Tcelna. OPXA's lead product candidate is in Phase IIb trials in patients with secondary progressive MS, and has received FDA fast-track designation. Serono gains global development and commercial rights to Tcelna.
From other sites
Comments (1)
  • biochemist
    , contributor
    Comments (354) | Send Message
     
    This deal is with Merck Serono (MKGAY) not MRK.
    5 Feb 2013, 01:10 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector